Their work distinguishes 3 main areas relevant to the assessment of disease severity in IBD: impact of the disease on the patient, disease burden, and disease progression.44 These 3 aspects were used as a guide to define criteria for disease severity in our study population.44 In our study, the impact of the disease on the patient was objectified using the GSRS.37 For disease burden and disease progression, serum C-reactive protein, fecal calprotectin, disease distribution, and macroscopic activity determined by endoscopy were considered. This evidence concerns the gene CRP and irritable bowel syndrome.